Agfa HealthCare has signed a contract with the National Heart Centre (NHC) of Singapore, the national referral centre for cardiovascular diseases and part of the Singapore Health Services (SingHealth) public healthcare cluster. The installation will include Agfa Heartlab Cardiovascular solution, a Web-based cardiovascular information system comprised of image management, structured reporting and a web-based portal.

Phase III of CoreValve’s international trial for its patented 18-French Revalving System is now one-third enrolled since beginning less than three months ago.

The unique 18-F-sized delivery catheter, has been used successfully to percutaneously implant its proprietary porcine pericardial-tissue bioprosthesis over the diseased aortic heart valves of more than 30 patients in a “cath” lab setting. The safety-and-efficacy clinical trial is expected to enroll 100 patients or more at 12 sites in Europe and Canada.

The FDA will revisit a device tomorrow that it cleared for U.S. sale three years ago — drug-eluting stents will be the subject of a two-day, 18-hour meeting of FDA’s Circulatory System Devices Panel of the Medical Devices Advisory Committee, Dec. 7 and 8 at the Hilton Washington DC North in Gaithersburg, MD.

The committee will discuss and make recommendations regarding issues related to stent thrombosis in coronary drug-eluting stents. Oral presentations from the public are slated throughout the committee’s deliberations on both days.

The FDA was notified on Dec. 2 that Pfizer will suspend a large, Phase 3 trial evaluating the investigational cardiovascular therapy torceptrapib/atorvastatin (T/A) due to an increased rate of mortality (death) in patients receiving the combination compared to those receiving atorvastatin alone. The agency says it fully supports Pfizer’s decision.

The American Heart Association has published a report demonstrating that adolescent boys have a significantly increased risk of high systolic blood pressure compared to adolescent girls. That fact may account for the higher prevalence of adult hypertension among men compared to women identified in previous studies, researchers report in “Circulation: Journal of the American Heart Association.”

One of the major dilemmas faced by clinicians in the Intensive Care Unit (ICU) is the determination of volume status and the predictability of the response to volume administration. Many of these patients are also hypotensive and in need of hemodynamic assessment. The evaluation of the hemodynamic status is often complicated by body habitus and medical condition. Previous methods of monitoring include echocardiography and the placement of a pulmonary artery catheter.


Pulse oximetry, which directly monitors the patient's oxygenation, came into its own as standard medical practice 20 years ago. It was about that time that its companion application, capnography, was first introduced to the medical community in the U.S.
Capnography continually and instantaneously monitors a patient's carbon dioxide concentrations in respiratory gases and is an indirect monitor of oxygenation that helps in the diagnosis of hypoxia so that corrective measures can be taken.

Recent downplay of the media’s attention to DES-related thrombosis during both the TCT and AHA conferences this fall may have been premature in light of a new study coming out of the Cleveland Clinic.

A meta-analysis published in the December issue of the American Journal of Medicine indicates that patients with drug-eluting stents have a four to five-fold increased relative risk for developing late thrombosis compared to those with bare-metal stents. It is the first published analysis of its kind, PRNewswire reports.

The Society for Cardiac Angiography and Interventions (SCAI) has extended the abstract deadline for its 30th Annual Scientific Sessions in Orlando, May 9-12, 2007. The new deadline is December 22, 2006 at midnight (EST).

The top three abstracts will received awards, and the top 10 abstracts selected will be featured for oral presentantion. All accepted abstracts will be published in the May 2007 edition of SCAI's Journal, “Catheterization and Cardiovascular Interventions.”

CV Therapeutics has announced it will file a new drug application to the FDA for its regadenoson agent in mid-2007 following positive results from a late-stage trial, the Associated Press reported Monday.

Regadenoson is used in myocardial perfusion imaging studies, or studies on coronary artery disease. CV Therapeutics said in late-stage trials regadenoson was comparable to Adenoscan, another drug used in MPI studies.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now